Pipeline
Core Global Development Pipeline of ONO
| Product Name | Mechanism | Target Disease | Development Stage | Country / Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Filing | Approval | |||||
| ONO-4059 | BTK inhibitor | Primary central nervous system lymphoma | US | In-house | |||||
| Pemphigus | JP | ||||||||
| Generalized scleroderma | JP | ||||||||
| ONO-7475 | Axl/Mer inhibitor | Acute leukemia | US | In-house | |||||
| Solid tumor | JP | ||||||||
| Non-small cell lung cancer | JP | ||||||||
| ONO-2910 | Enhancement of Schwann cell differentiation | Peripheral nerve disorder | JP | In-house | |||||
| ONO-4578 | PG receptor (EP4) antagonist | Solid tumor・Gastric cancer | JP | In-house | |||||
| Colorectal cancer | JP | ||||||||
| Pancreatic cancer | JP | ||||||||
| Non-small cell lung cancer | JP | ||||||||
| ONO-2808 | S1P5 receptor agonist | Neurodegenerative disease | JP・EU | In-house | |||||
| ONO-7684 | FXla inhibitor | Thrombosis | EU | In-house | |||||
| ONO-4685 | PD-1 x CD3 bispecific antibody | Autoimmune disease | JP | In-house | |||||
| ONO-2909 | PG receptor (DP1) antagonist | Narcolepsy | JP | In-house | |||||
As of 26 July, 2021
